In addition, the expression levels of inhibitory receptors such as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), PD-1, and CTLA-4 in CD4+ or CD8+ T cells can be applied to predict the response to lung cancer immunotherapy [40–42]. This evidence concerns the gene LAG3 and lung carcinoma.